Global Health Matters

26 July 2021 - By Thomas B. Cueni
Developing COVID-19 vaccines in less than a year was a monumental achievement – but to improve the efficacy, manufacture and distribution of vaccines and combat emerging variants, governments, regulators and research scientists must work together to drive further innovation. Imagine if scientists invented a COVID-19 vaccine that can be given ...
Read More
21 July 2021 - By Greg Perry
At this year’s regional World Health Summit in Uganda, we had the pleasure of showcasing the research fellows that IFPMA has been supporting as part of the Chatham House African Public Health Leaders fellowship program since 2016 in an event titled “Will COVID-19 dictate a new paradigm in Africa?” This ...
Read More
19 July 2021 - By Laetitia Bigger
We have a realistic hope of producing 11 billion COVID-19 vaccines by the end of 2021 to vaccinate the world’s whole adult population. With increased dose sharing and urgent measures to ensure vaccine equity through COVAX and other bilateral agreements, we would like to see many more vaccines reaching all ...
Read More
7 July 2021 - By Komal Kalha
To put an end to the pandemic, industry was tasked with manufacturing and supplying billions of COVID-19 vaccines, starting from zero. This monumental task is on its way to being achieved, with 11 billion doses forecast for the end of 2021[1]—enough for the world’s adult population, according to the World ...
Read More
28 June 2021 - By Greg Perry
Boosting production of COVID-19 vaccines is key to ensuring there are enough doses for all populations most at risk. But manufacturing COVID-19 vaccines at the volumes the world needs is a colossal challenge and scarcity of raw materials and trade barriers could upset estimates that 11 billion doses – enough ...
Read More
25 June 2021 - By Paula Barbosa
This blog was originally published on the Media Planet Campaign Value of Vaccines on 25 June 2021. Over the past few decades, the global regulatory environment has become more stringent and demanding to consistently guarantee the quality, safety and efficacy of medicines and vaccines. The increase in requirements by regulatory ...
Read More
24 June 2021 - By Thomas B. Cueni
Step 1 of the biopharmaceuticals 5-step plan to address vaccine equity A number of countries with access to sufficient doses to vaccinate their own populations have pledged 1 billion doses so far for low- and middle-income (LMIC) countries in 2021 and 2022. We now need to ensure those pledges are ...
Read More
23 June 2021 - By Amadou Diarra
In light of the recent G7 Summit 2021, where the COVID-19 pandemic was understandably the overarching point of discussions, I was reminded about the key role our industry is playing in this health and economic crisis. This pandemic, the like of which has not been seen in over 100 years, ...
Read More
16 June 2021 - By Thomas B. Cueni
This oped was originally published on in the Down to Earth (16-30 June 2021 Edition). Scarcity of raw materials and trade barriers could dent hopes for 10 billion vaccines produced by end of 2021 Back in March 2020, vaccine innovator companies started working on how they would set up manufacturing ...
Read More
15 June 2021 - By Thomas B. Cueni
Original article published on Taggesspigel on 15 June 2021.  Mr Cueni, of all things, the COVID-19 pandemic, triggered by a virus, could further fuel the development of resistance in bacteria: many Covid 19 patients in hospitals are given antibiotics unnecessarily. G-7 health ministers are warning of a "creeping pandemic" and ...
Read More
9 June 2021 - By Thomas B. Cueni
Talking to CNBC-TV18's Parikshit Luthra (4 June 2021), IFPMA Director General Thomas Cueni shared his perspective on global vaccine supplies. Main interview highlights from Thomas Cueni: We from IFPMA called out to governments across the world to join us in a five-step plan to urgently address vaccine equity. The first ...
Read More
researchers lab work
4 June 2021 - By Sally Davies & Thomas Cueni
This oped has been originally published on The Telegraph on 3rd June 2021. Professor Dame Sally Davies, UK Special Envoy on Antimicrobial Resistance Thomas Cueni, Director General, International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) In 2016, the United States National Security Council[1]drew up a playbook on fighting pandemics so ...
Read More
3 June 2021 - By James Anderson
This oped was originally published on Foresight Global Health on 3rd June 2021. Innovations in diabetes treatment and management have made enormous contributions to global health over the past 100 years, but there are still obstacles that must be overcome to slow the growth of the disease and reduce its ...
Read More
20 May 2021 - By Janis Bernat
This blog was originally published on Media Planet Clinical Trials Campaign on 20 May 2021.  “The biopharmaceutical industry and regulatory authorities have been working to ensure clinical trials have been progressing in all diseases throughout the global pandemic. When the COVID-19 pandemic began, most of our focus went to ‘how ...
Read More
Influenza Version vom 14.07.2006
29 April 2021 - By Thomas B. Cueni
This oped was originally published on International Business Times on 11 April 2021. Imagine if China had refused to share Covid-19's genetic sequences with other countries. Vaccine development would have been delayed indefinitely. Monitoring the virus would have been next to impossible. Thankfully, that didn't happen. Chinese scientists shared the ...
Read More
1 2 3 14